VTVT - vTv Therapeutics Inc Stock Price, Fair Value and News

$16.19+1.53 (+10.44%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

VTVT Price Action

Last 7 days

15.7%


Last 30 days

17.2%


Last 90 days

15.4%


Trailing 12 Months

94.1%

VTVT RSI Chart

MayJunJulAugSepOctNovDec20250102030405060708090

VTVT Valuation

Market Cap

51.6M

Price/Earnings (Trailing)

-2.82

Price/Sales (Trailing)

19.29

EV/EBITDA

-0.45

Price/Free Cashflow

-2.21

VTVT Price/Sales (Trailing)

2022202320241020304050

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VTVT Fundamentals

VTVT Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

20142016201820202022202402M4M6M8M10M12M

VTVT Earnings

Earnings (TTM)

-18.3M

Earnings Growth (Yr)

28.12%

Earnings Growth (Qtr)

7.66%

201420162018202020222024-50M-40M-30M-20M-10M0

VTVT Profitability

EBT Margin

-1120.37%

Return on Equity

-121.97%

Return on Assets

-42.41%

Free Cashflow Yield

-45.31%

VTVT Investor Care

Shares Dilution (1Y)

22.00%

Diluted EPS (TTM)

-4.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20142015201620172018201920202021202202M4M6M8M10M12M
Net sales
YearQ1Q2Q3Q4
20240000
20230000
20225.0M5.0M2.0M2.0M
20215.8M5.2M4.6M4.0M
20200006.4M
201911.3M10.6M7.3M2.8M
20182.3M4.8M8.1M12.4M
2017288.0K119.0K96.0K291.0K
2016845.0K917.0K822.0K634.0K
20151.3M1.0M776.5K519.0K
20141.1M1.3M1.4M1.5M
2013000976.0K
Get all data in R, Python etc through our Historical Stock Data APIs
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

vTv Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for vTv Therapeutics Inc? What does VTVT stand for in stocks?

VTVT is the stock ticker symbol of vTv Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of vTv Therapeutics Inc (VTVT)?

As of Fri Jan 31 2025, market cap of vTv Therapeutics Inc is 51.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTVT stock?

You can check VTVT's fair value in chart for subscribers.

Is vTv Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VTVT is over valued or under valued. Whether vTv Therapeutics Inc is cheap or expensive depends on the assumptions which impact vTv Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTVT.

What is vTv Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 31 2025, VTVT's PE ratio (Price to Earnings) is -2.82 and Price to Sales (PS) ratio is 19.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTVT PE ratio will change depending on the future growth rate expectations of investors.